BioCryst Pharmaceuticals saw a 6.7% quarter-over-quarter revenue increase for its drug Orladeyo, reaching $158.2 million in Q2. The company also reduced its royalty financing obligations from $465.7 million at the end of 2025 to $426.8 million by June. Additionally, BioCryst's acquisition of navenibart, a potential treatment for hereditary angioedema (HAE), is viewed as a strategic move that supports a positive risk/reward profile, with analysts projecting a 149% upside in stock price. This positions BioCryst as an attractive investment opportunity in the HAE market following recent industry activity like Chiesi's acquisition of KalVista.
TSMC reports that demand for AI chips remains significantly higher than its production capacity. This supply-demand gap highlights the strong growth potential in the AI semiconductor market. As a result, investors see Nvidia, a leading AI chipmaker, ...
Hedera saw a 168.37% increase in transactions per second and a 12.3% rise in total value locked to $33.2 million over 30 days, signaling strong network activity. However, the HBAR token price fell 2.7% in 24 hours and 9.5% weekly, despite a 14.9% mon...
In Argentina's peer-to-peer (P2P) cryptocurrency markets, Tether (USDT) is trading at a significant premium compared to the official dollar reference rate set by the central bank. Binance's median buy quote for USDT reached 1,612.6 pesos, about 6.6% ...
With the holiday season approaching, several credit cards are offering attractive sign-up bonuses that reward holiday spending. Cards like Chase Freedom Flex, Bank of America Customized Cash Rewards, Hilton Honors American Express Surpass, and Chase ...
On October 16, U.S. XRP spot ETFs experienced a net outflow of $2.4734 million, entirely from the Canary XRP ETF. Despite this daily withdrawal, the Canary XRP ETF has a historical net inflow of $484 million. Overall, XRP spot ETFs have accumulated $...
